Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |
| University of Surrey | OTHER |
| University of Oxford | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and incidence of psychiatric co-morbidities in people with alopecia areata, (3) the prevalence and incidence of autoimmune and atopic conditions in people with alopecia areata, and (4) the incidence of common infections in people with alopecia areata.
The overall purpose of the first study (Study 1) is to describe the epidemiology of Alopecia areata (AA) and to assess the current level of primary care service utilisation and management patterns associated with patients diagnosed with AA.
The overall purpose of the second study (study 2) is to assess the prevalence and incidence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients diagnosed with AA relative to a control population of patients without a diagnosis of AA. In addition, the study will determine both the treatment, 'sick day' and unemployment burden. Treatment burden comprises that of medications and psychological interventions used to treat mental health conditions in adult patients diagnosed with Alopecia areata.
The overall purpose of the third study (Study 3) is to assess the prevalence and incidence of atopic and autoimmune conditions in adult patients diagnosed with AA relative to a control population of patients without AA.
The overall purpose of the fourth study (Study 4) is to assess the incidence of common infections in adult patients diagnosed with AA relative to a control population of patients without AA.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cases | Patients with a confirmed diagnosis of Alopecia areata within the study period will be included as cases for analysis. |
| |
| Controls | The control cohorts will be defined by matching cases with patients who have never been diagnosed with Alopecia areata either prior to or during the study period, by age and sex, at General Practice practice level. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exposure of interest (studies 2 & 3). | Other | Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis |
| Measure | Description | Time Frame |
|---|---|---|
| Study 1: The incidence of Alopecia Areata | The incidence of Alopecia areata within the study cohort during the study period | Overall during 2009-2018 inclusive |
| Study 1: The incidence of Alopecia Areata stratified by sociodemographic factors | This will comprise of the incidence of Alopecia Areata over the study period, by age group, gender, ethnicity, and Social Economic Status. | Overall during 2009-2018 inclusive |
| Study 1:The annual rate of primary care visits for people with Alopecia Areata. | The annual rate of visits to primary care for any reason within one year of diagnosis. | Within one year of diagnosis of Alopecia Areata |
| Study 1: Secondary care dermatology service utilisation | The percent of people reviewed in secondary care dermatology services within one year of diagnosis of Alopecia Areata | Within one year of diagnosis of Alopecia Areata |
| Study 2: The prevalence of common mental health conditions in adult patients diagnosed with Alopecia Areata at the time of diagnosis | Prevalence of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients diagnosed with Alopecia Areata in a contemporary real-world population compared with matched controls. | At the time of diagnosis in all patients diagnosed with Alopecia Areata 2009-2018 inclusive |
| Study 2: Describe the incidence of common mental health conditions in adult patients with Alopecia Areata | Incidence of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. |
| Measure | Description | Time Frame |
|---|---|---|
| Study 1: Adjusted incidence rate ratios of Alopecia Areata within England by geographic region. | By region across England. | Overall during 2009-2018 inclusive |
| Study 2: Prevalence (percentage) of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder), by socio-demographic factors, in adult patients diagnosed with Alopecia Areata. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
These studies will use routinely collected and collated data from the Royal College of General Practitioners Research and Surveillance Centre database to provide a broadly representative sample of the population of England.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrew McGovern, MD | Momentum Data | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Momentum Data Ltd | London | WC1X 8QT | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35157313 | Derived | Macbeth AE, Holmes S, Harries M, Chiu WS, Tziotzios C, de Lusignan S, Messenger AG, Thompson AR. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol. 2022 Jul;187(1):73-81. doi: 10.1111/bjd.21055. Epub 2022 May 11. | |
| 34785540 | Derived |
Not provided
Not provided
Individual patient data is confidential but can be made available in an anonymised form to bone fide researchers subject to the required data protection training and other requirements. All data will remain behind a firewall and will only be available for access through a secured computer network.
There is no pre-specified time-frame for data availability; this will be considered on an individual basis for each request.
As above
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Within two years of diagnosis of Alopecia Areata |
| Study 2: Describe the mental health medication treatment burden of adult patients diagnosed with Alopecia Areata. | This will comprise of the number of medications used to treat mental health conditions in patients diagnoses with Alopecia Areata. Antidepressant medication classes to be examined comprise; selective serotonin reuptake inhibitors and related medications (serotonin and norepinephrine reuptake inhibitors (SNRIs)), tricyclic antidepressants and related medications (tetracyclic antidepressant), and monoamine oxidase inhibitors. Anxiolytic medications to be examined comprise all benzodiazepines and other related medications indicated for use in anxiety states. | Within two years of diagnosis of Alopecia Areata |
| Study 2: Number of patients diagnosed with Alopecia Areata receiving mental health psychological intervention. | This will comprise of the number of psychological interventions used to treat mental health conditions in patients diagnoses with Alopecia Areata. Psychological interventions comprise of counselling, Cognitive Behavioural Therapy, and psychotherapy. | Within two years of diagnosis of Alopecia Areata |
| Study 3: Describe the prevalence of atopic and autoimmune conditions in adult patients diagnosed with Alopecia Areata at the time of diagnosis | Prevalence of atopic and autoimmune conditions in adult patients diagnosed with Alopecia Areata in a contemporary real-world population at diagnosis compared with matched controls. | At the time of diagnosis in all patients diagnosed with Alopecia Areata 2009-2018 inclusive |
| Study 3: Describe the incidence of atopic and autoimmune conditions in adult patients with Alopecia Areata. | Incidence of atopic and autoimmune conditions in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of a composite of common infections in adult patients with Alopecia Areata | Incidence of a composite of any common infection (composite comprising a diagnosis of: upper and lower respiratory tract infection, pneumonia, acute bronchitis, influenza, skin infection, urinary tract infection, genital infections, gastrointestinal infection, herpes simplex and herpes zoster) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of a composite of viral infections in adult patients with Alopecia Areata | Incidence of a composite of any viral infection (composite comprising a diagnosis of: influenza, herpes simplex and herpes zoster infections, bronchitis, and any upper respiratory tract infections specifically coded as being viral) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
By age group, gender, ethnicity, and Social Economic Status. |
| At the time of diagnosis in all patients diagnosed with Alopecia Areata 2009-2018 inclusive |
| Study 2: Describe the burden of 'sick days' in adult patients diagnosed with Alopecia Areata relating to mental health conditions. | Sick days will be indicated by the issuing of Med 3 certification from primary care (Statement of Fitness for Work) certification. | Within one year of diagnosis of Alopecia Areata |
| Study 2: Describe the prevalence of unemployment in adult patients diagnosed with Alopecia Areata. | Unemployment will be identified using Read codes relating to unemployment recorded in the clinical record or the issuing of an Incapacity Benefit (IB113) or Employment and Support Allowance (ESA113) form. | Within one year of diagnosis of Alopecia Areata |
| Study 4: The incidence of upper respiratory tract infection in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of upper respiratory tract infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of lower respiratory tract infection in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of lower respiratory tract infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of influenza infection in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of influenza or influenza-like illness (where direct swab confirmed diagnosis is not performed) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of acute bronchitis in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of acute bronchitis in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of pneumonia in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of pneumonia in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of gastrointestinal infection in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of gastrointestinal infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of stool confirmed gastrointestinal infection in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of gastrointestinal infection confirmed by stool culture or microscopy results (or other microbiological diagnosis confirmation) in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of skin infection in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of skin infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of urinary tract infection in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of urinary tract infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of genital infection in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of genital infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of herpes zoster infection in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of herpes zoster infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Study 4: The incidence of herpes simplex infection in adult patients with Alopecia Areata | Incidence of any recorded diagnosis of herpes simplex infection in adult patients with Alopecia Areata in a contemporary real-world population compared with matched controls. | Within five years of Alopecia Areata diagnosis |
| Harries M, Macbeth AE, Holmes S, Thompson AR, Chiu WS, Gallardo WR, Messenger AG, Tziotzios C, de Lusignan S. Epidemiology, management and the associated burden of mental health illness, atopic and autoimmune conditions, and common infections in alopecia areata: protocol for an observational study series. BMJ Open. 2021 Nov 16;11(11):e045718. doi: 10.1136/bmjopen-2020-045718. |
| ID | Term |
|---|---|
| D000506 | Alopecia Areata |
| D003866 | Depressive Disorder |
| D001008 | Anxiety Disorders |
| D003876 | Dermatitis, Atopic |
| D065631 | Rhinitis, Allergic |
| D001249 | Asthma |
| D003424 | Crohn Disease |
| D003093 | Colitis, Ulcerative |
| D000752 | Anemia, Pernicious |
| D003922 | Diabetes Mellitus, Type 1 |
| D050031 | Hashimoto Disease |
| D006111 | Graves Disease |
| D001172 | Arthritis, Rheumatoid |
| D015535 | Arthritis, Psoriatic |
| D013167 | Spondylitis, Ankylosing |
| D008180 | Lupus Erythematosus, Systemic |
| D011111 | Polymyalgia Rheumatica |
| D012859 | Sjogren's Syndrome |
| D011565 | Psoriasis |
| D014820 | Vitiligo |
| D009103 | Multiple Sclerosis |
| D002446 | Celiac Disease |
| D012141 | Respiratory Tract Infections |
| D007251 | Influenza, Human |
| D001991 | Bronchitis |
| D011014 | Pneumonia |
| D002481 | Cellulitis |
| D014552 | Urinary Tract Infections |
| D006562 | Herpes Zoster |
| D006561 | Herpes Simplex |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D003863 | Depression |
| D001327 | Autoimmune Diseases |
| ID | Term |
|---|---|
| D000505 | Alopecia |
| D007039 | Hypotrichosis |
| D006201 | Hair Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D012220 | Rhinitis |
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D012130 | Respiratory Hypersensitivity |
| D010038 | Otorhinolaryngologic Diseases |
| D001982 | Bronchial Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
| D003092 | Colitis |
| D003108 | Colonic Diseases |
| D000749 | Anemia, Megaloblastic |
| D000748 | Anemia, Macrocytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D014806 | Vitamin B 12 Deficiency |
| D014804 | Vitamin B Deficiency |
| D001361 | Avitaminosis |
| D003677 | Deficiency Diseases |
| D044342 | Malnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D013967 | Thyroiditis, Autoimmune |
| D013966 | Thyroiditis |
| D013959 | Thyroid Diseases |
| D005094 | Exophthalmos |
| D009916 | Orbital Diseases |
| D005128 | Eye Diseases |
| D006042 | Goiter |
| D006980 | Hyperthyroidism |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D025242 | Spondylarthropathies |
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D017444 | Skin Diseases, Papulosquamous |
| D000089183 | Axial Spondyloarthritis |
| D000844 | Ankylosis |
| D009135 | Muscular Diseases |
| D014987 | Xerostomia |
| D012466 | Salivary Gland Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D015352 | Dry Eye Syndromes |
| D007766 | Lacrimal Apparatus Diseases |
| D017496 | Hypopigmentation |
| D010859 | Pigmentation Disorders |
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D008286 | Malabsorption Syndromes |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
| D012874 | Skin Diseases, Infectious |
| D013492 | Suppuration |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D000073618 | Varicella Zoster Virus Infection |
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D017193 | Skin Diseases, Viral |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided